TTC7A and inflammatory bowel disease: Most monogenic IBD patients are resistant to conventional medical treatment (Heyman et al., 2005; Kelsen et al., 2019; Shim, 2019), as are patients with neonatal-onset IBD with TTC7A deficiency.